2022-23 Academic Calendar (PDF)
« All Events
Please join us for PhD Student, Kent Young, Senior Manager, Process Engineering, Kite Pharma PhD Dissertation Literature Mastery Presentation.
There are patients alive today because chimeric antigen receptor T (CAR-T) cell therapy exists. CAR-T cell therapy is a unique treatment that utilizes a patient’s own cells as the starting material for their disease. After undergoing a leukapheresis (aph) process, their aph is shipped to a GMP manufacturing facility where it is processed by technicians with special equipment, materials, reagents, and software. From there, T cells are enriched, activated, genetically edited, expanded, harvested, formulated, cryopreserved, then shipped back to the patient for infusion. The manufacturing process is logistically challenging and complex. At any stage in the process, interruptions may delay the patient from receiving their treatment. CAR-T cell therapy has mainly focused on treating blood cancers such as B cell lymphomas, acute lymphoblastic lymphoma, and multiple myeloma; however, promising results in early studies for the autoimmune disease, gynecological malignancies, and solid tumors is paving the way for wider adoption of this paradigm changing therapy. Improving manufacturing outcomes by understanding the process challenges in T cell selection may hold the key to increasing accessibility of this life-saving drug and improving standard of care.
Date: Friday, November 4, 2022
Time: 12:00 – 1:00 p.m.
Location: 121 Bldg. – 1111 Classroom AND Via Zoom (See Outlook Invite for Zoom link)
Celebrating 25 years of innovation! 25.kgi.edu.